I-A09

• Description :

  I-A09 and its derivatives, specifically 1,2,3-triazole-adamantylacetamide hybrids (5a–u), exhibit significant antitubercular activity. These hybrids were synthesized using copper-catalyzed click chemistry, combining bioactive fragments from antitubercular I-A09 and substituted adamantyl urea. The compound N- (1-adamantyl) -2-azido acetamide was reacted with various alkyl/aryl acetylenes to produce new analogues. Among them, N- (1-adamantan-1-yl) -2- (4- (phenanthren-2-yl) -1H-1,2,3-triazol-1-yl) acetamide (5t) showed the most promise with a minimum inhibitory concentration (MIC) of 3.12 μg/mL against Mycobacterium tuberculosis H37Rv, and a selectivity index greater than 15[1].

• UNSPSC :

  12352005

• Target :

  Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/i-a09.html

• Smiles :

  O=C(C1=CC2=C(C=C1O)OC(C3=CC=CC=C3)=C2C4=CN(CC(NC5=CC=C(N6CCOCC6)C=C5)=O)N=N4)O

• Molecular Formula :

  C29H25N5O6

• Molecular Weight :

  539.54

• References & Citations :

  [1]Design, synthesis and evaluation of 1,2,3-triazole adamantylacetamide hybrids as potent inhibitors of Mycobacterium tuberculosis

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1143579-76-3]